Eribulin mesilate + Irinotecan hydrochloride
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory or Recurrent Solid Tumors
Conditions
Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
Trial Timeline
Mar 5, 2018 → May 17, 2021
NCT ID
NCT03245450About Eribulin mesilate + Irinotecan hydrochloride
Eribulin mesilate + Irinotecan hydrochloride is a phase 1/2 stage product being developed by Eisai for Refractory or Recurrent Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03245450. Target conditions include Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma.
What happened to similar drugs?
3 of 20 similar drugs in Refractory or Recurrent Solid Tumors were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03245450 | Phase 1/2 | Completed |
Competing Products
20 competing products in Refractory or Recurrent Solid Tumors